SMMT Q4 2025 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$4,355

Operating Income

$57M

Net Income

-$219M

EPS (Diluted)

$-0.29

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$100M

Stock-Based Comp.

$243M

Balance Sheet

Total Assets

$751M

Total Liabilities

$92M

Stockholders' Equity

$659M

Cash & Equivalents

$225M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$4,355	-$15M	+100.0%
Operating Income	$57M	-$66M	+187.3%
Net Income	-$219M	-$61M	-258.1%